Germany’s G-BA To Act As Coordinator In New EMA-HTA Parallel Scientific Advice Approach
A new format for obtaining parallel scientific advice from the European Medicines Agency and national health technology assessment bodies in Europe is coming soon.
You may also be interested in...
A report published by the European Medicines Agency highlights milestones reached under its collaboration with EUnetHTA over recent years and outlines areas for further development once the initiative changes hands under the new HTA Regulation.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
Quviviq is to become the first dual orexin receptor antagonist available on the National Health Service. Just over 20,000 people in England could receive treatment with the drug in its first year, says the health technology assessment institute, NICE.